@article{oai:shiga-med.repo.nii.ac.jp:00000176,
 author = {藤本, 優貴 and 三矢, 幸一 and 横井, 俊浩 and 林, 央周 and 中洲, 庸子 and 野崎, 和彦},
 issue = {1},
 journal = {滋賀医科大学雑誌},
 month = {Apr},
 note = {Departmental Bulletin Paper, [Background] Temozolomide(TMZ) is a standard chemotherapeutic agent for patients with high-grade gliomas.Although lymphocytopenia is known as one of the adverse events in TMZ treatment, only few studies reported its timingand clinical course during initial concomitant and maintenance regimens. [Materials and Methods] Between January 2010and August 2013, we experienced 82 patients with gradeⅢ to Ⅳ (in WHO classification) glioma treated at ShizuokaCancer Center, and all of the consecutive patients’ clinical data were analyzed retrospectively focusing on lymphocytpenia.Fifty-seven patients out of 82 completed concomitant treatment with the combination of TMZ (75mg/m2) and radiotherapy,54 to 60Gy for six weeks. Twenty-two patients completed adjuvant TMZ over six cycles, taking TMZ at 150 to 200mg/m2daily for five days per 28 days at a cycle. GradeⅡ to Ⅳ (in CTCAE ver.4) lymphocytopenia and neutorocytepenia weredefined as adverse reactions. [Results] Lymphocytopenia was observed in 45 patients (78.9%) during concomitant and nine(40.9%) during maintainance treatments. Neutrocytopenia appeared in 11 patients (19.3%) during concomitant, and one(1.8%) during maintainance treatments. [Conclusions] In this research, we observed lymphocytopenia more frequently thanneutrocytopenia, especially during initial daily treatment of TMZ concomitant with radiotherapy. Although TMZ is one ofthe widely used and effective chemotherapeutic drugs for high-grade gliomas, continuous TMZ therapy results in robustdepletion of lymphocytes that may lead to opportunistic infections. TMZ should be taken carefully, with regular monitoringof blood cell count and hemogram, under adequate amount and doze schedules.},
 pages = {42--48},
 title = {悪性神経膠腫患者のテモゾロミド療法におけるリンパ球減少},
 volume = {27},
 year = {2014}
}